No Data
No Data
Small-cap Stocks Have Climbed Recently. Here Are the Ones Most Poised for Further Upside
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BTIG Maintains CareDx(CDNA.US) With Buy Rating, Maintains Target Price $40
BTIG analyst Mark Massaro maintains $CareDx(CDNA.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 30.8% and a total average
Buy Rating Affirmed for CareDx: Leadership Enhancements and Undervalued Stock Present Growth Opportunities
CareDx Announces Key Executive Appointments and Investor Day
CareDx Names Keith Kennedy as COO